Biosplice Therapeutics Announces First Patient Dosed in InvestigatorInitiated Phase 1 Clinical Trial of Cirtuvivint and Olaparib in BRCA/HRD PlatinumResistant Ovarian Cancer
SAN DIEGO, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Biosplice Therapeutics, Inc. (“Biosplice”),…
RadioMedix and Vect-Horus Announce First Patient Dosed in Exploratory Clinical Study of 203Pb-RMX-VH-PIB for Glioblastoma Multiforme and Pancreatic Ductal Adenocarcinoma
Marks a significant milestone in ongoing collaboration between RadioMedix and Vect-Horus to…
FIRST PATIENT DOSED IN CITRYLLS PHASE IIA TRIAL EVALUATING CIT-013 IN RHEUMATOID ARTHRITIS
Randomized multi-center study designed to assess the efficacy, safety, and tolerability of…
